- Home
- HRMY vs OLMA Comparison
HRMY vs OLMA Comparison
Compare HRMY & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | OLMA |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HRMY | OLMA |
|---|---|---|
| Price | $31.52 | $13.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $44.11 | ★ $44.89 |
| AVG Volume (30 Days) | 651.7K | ★ 940.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 15.00 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $12.88 | N/A |
| P/E Ratio | $57.36 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $3.89 |
| 52 Week High | $40.87 | $36.26 |
Technical Indicators
Market Signals| Indicator | HRMY | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 37.44 |
| Support Level | $25.92 | $12.87 |
| Resistance Level | $33.11 | $17.23 |
| Average True Range (ATR) | 0.93 | 0.87 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 87.38 | 18.78 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.